2,4-Diisopropyl-1-methyl-imidazol | 37455-76-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,4-Diisopropyl-1-methyl-imidazol
• 英文别名: 2,4-diisopropyl-1-methyl-1H-imidazole；1-Methyl-2,4-di(propan-2-yl)imidazole
• CAS: 37455-76-8
• 化学式: C₁₀H₁₈N₂
• 分子量: 166.266
• InChiKey: ZGENGUIVVZGAJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,4-Diisopropyl-1-methyl-imidazol 、 聚合甲醛 生成 (2,5-diisopropyl-3-methyl-3H-imidazol-4-yl)-methanol
  参考文献：
  名称：

  MASUI M.; SUDA K.; INOUE M.; IZUKURA K.; YAMAUCHI M., CHEM. AND PHARM. BULL. , 1974, 22, NO 10, 2359-2364

  摘要：

  DOI：

文献信息

• ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20180110873A1

  公开（公告）日：2018-04-26

  A compound capable of inhibiting cell proliferation, having a structure according to formula (I) wherein the variables in formula (I) are as defined in the specification. Such compounds are useful as anti-cancer agents, especially in antibody-drug conjugates.

  一种能够抑制细胞增殖的化合物，其结构符合以下公式（I） 其中公式（I）中的变量如规范中所定义。这些化合物可用作抗癌药物，特别是在抗体药物结合物中。
• Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
  申请人：Mutel Vincent

  公开号：US20050131043A1

  公开（公告）日：2005-06-16

  This invention relates to a compound and the use of the compound of the formula wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description, A signifies —CH═CH— or —C≡C—; and B signifies wherein R 6 to R 26 , X and Y are as defined in the specification or a pharmaceutically acceptable salt thereof, for use in pharmaceutical compositions for the treatment or prevention of mGluR5 receptor mediated disorders.

  本发明涉及一种化合物及其使用，该化合物的化学式为其中R1、R2、R3、R4和R5如描述中所定义，A表示—CH═CH—或—C≡C—；B表示其中R6至R26、X和Y如规范中所定义或其药学上可接受的盐，用于制备药物组合物，用于治疗或预防mGluR5受体介导的疾病。
• Viral Polymerase Inhibitors
  申请人：Beaulieu Louis Pierre

  公开号：US20070142380A1

  公开（公告）日：2007-06-21

  An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R 2 , R 3 , L, M 1 , M 2 , M 3 , M 4 , Y 1 , Y 0 , Z and Sp are as defined in claim 1 , or a salt thereof, as an inhibitor of HCV NS5B polymerase.

  一种化合物的同分异构体、对映异构体、非对映异构体或互变异构体，其化学式为I：其中A、B、R2、R3、L、M1、M2、M3、M4、Y1、Y0、Z和Sp如权利要求1所定义，或其盐，作为HCV NS5B聚合酶的抑制剂。
• FACTOR Xa INHIBITORS
  申请人：Zhu Bing-Yan

  公开号：US20070185092A1

  公开（公告）日：2007-08-09

  The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

  本发明涉及由式（I）表示的化合物，或其药学上可接受的盐、酯或前药，其是因子Xa的抑制剂。本发明还涉及用于制备这种化合物的中间体，含有这种化合物的制药组合物，用于预防或治疗由不良血栓形成所表征的多种疾病的方法，以及抑制血液样品凝血的方法。
• FACTOR XA INHIBITORS
  申请人：Zhu Bing-Yan

  公开号：US20100234352A1

  公开（公告）日：2010-09-16

  The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

  本发明涉及由式（I）表示的化合物或其药学上可接受的盐、酯或前药，其为因子Xa的抑制剂。本发明还涉及制备这些化合物所使用的中间体，含有这些化合物的药物组合物，预防或治疗一些以不需要的血栓形成为特征的疾病的方法，以及抑制血样的凝血方法。